De-escalation therapy: Is it valuable for the management of ventilator-associated pneumonia?

Clinics in Chest Medicine

Volumn 32, Issue 3, 2011, Pages 517-534

  Niederman, Michael S ^a,b   Soulountsi, Vasiliki ^a,c  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c G PAPANICOLAOU HOSPITAL   (Greece)

Author keywords

Antimicrobial resistance; De Escalation; Therapeutic protocols; Ventilator associated pneumonia (VAP) therapy

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; C REACTIVE PROTEIN; CARBAPENEM; CEFEPIME; CIPROFLOXACIN; DORIPENEM; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; PROCALCITONIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM CULTURE; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CLINICAL PULMONARY INFECTION SCORE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; LUNG LAVAGE; MEDICAL DECISION MAKING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TRACHEAL ASPIRATION PROCEDURE; TREATMENT DURATION; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; HUMANS; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED;

EID: 80051871647     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2011.05.009     Document Type: Review

References (50)

1. Vincent J.L., Rello J., Marshall J., et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302:2323-2329.
2. Kollef M.H., Sherman G., Ward S., et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115:462-474.
3. Luna C.M., Vujacich P., Niederman M.S., et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997, 111:676-685.
4. Gaynes R., Edwards J.R. Overview of infections caused by gram-negative bacilli. Clin Infect Dis 2005, 41:848-854. National Nosocomial Infections Surveillance System.
5. Niederman M.S., Craven D.E., Bonten M.J., et al. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416.
6. Hoffken G., Niederman M.S. Nosocomial pneumonia: the importance of a de-escalating strategy for antibiotic treatment of pneumonia in the ICU. Chest 2002, 122:2183-2196.
7. Dellit T., Owens R., McGowan J., et al. Infectious Diseases Society of America and the society for healthcare epidemiology of america guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007, 44:159-177.
8. Niederman M.S. The importance of de escalating antimicrobial therapy in patients with ventilator associated pneumonia. Semin Respir Crit Care Med 2006, 27:45-50.
9. Niederman M.S. Use of broad spectrum antimicrobials for the treatment of pneumonia in seriously Ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms. Clin Infect Dis 2006, 42:S72-S81.
10. Soo Hoo G.W., Wen Y.E., Nguyen T., et al. Impact of clinical guideline in the management of severe hospital acquired pneumonia. Chest 2005, 128:2778-2787.
11. Lancaster J.W., Lawrence K.R., Fong J.J., et al. Impact of an institution-specific hospital-acquired pneumonia protocol on the appropriateness of antibiotic therapy and patient outcomes. Pharmacotherapy 2008, 28(7):852-862.
12. Kollef M.H., Morrow L.E., Niederman M.S., et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest 2006, 129:1210-1218.
13. Dellit T.H., Chan J.D., Skerrett S.J., et al. Development of a guideline for the management of VAP based on local microbiological findings and impact of the guideline on antimicrobial use practices. Infect Control Hosp Epidemiol 2008, 29(6):525-533.
14. Kollef M.H., Kollef K.E. Antibiotic utilization and outcomes for patients with clinically suspected ventilator-associated pneumonia and negative quantitative BAL culture results. Chest 2005, 128:2706-2713.
15. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 2006, 355:2619-2630. The Canadian Critical Care Trials Group.
16. Joffe A.R., Muscedere J., Marshall J.C., et al. The safety of targeted antibiotic therapy for ventilator-associated pneumonia: a multicenter observational study. J Crit Care 2008, 23:82-90.
17. Giantsou E., Liratzopoulos N., Efraimidou E., et al. De-escalation therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate. Intensive Care Med 2007, 33:1533-1540.
18. Leone M., Garcin F., Bouvenot J., et al. Ventilator-associated pneumonia: breeaking the vicious circle of antibiotic overuse. Crit Care Med 2007, 35:379-385.
19. Alvarez-Lerma F., Alvarez B., Luque P., et al. Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study. Crit Care 2006, 10:R78.
20. Nobre V., Harbarth S., Graf J.D., et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients. Am J Respir Crit Care Med 2008, 177:498-505.
21. Stolz D., Smyrnios N., Eggimann P., et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 2009, 34:1364-1375.
22. Eachempati S.R., Hydo L.J., Shou J., et al. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients?. J Trauma 2009, 66:1343-1348.
23. Bouadma L., Luyt C.E., Tubach F., et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010, 375:463-474.
24. Luna C.M., Blanzaco D., Niederman M.S., et al. Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 2003, 31:676-682.
25. Trouillet J.L., Chastre J., Vuagnat A., et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998, 157:531-539.
26. Beardsley J.R., Willamson J.C., Johnson J.W., et al. Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. Chest 2006, 130:787-793.
27. Rello J., Sa-Borges M., Correa H., et al. Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices. Am J Respir Crit Care Med 1999, 60:608-613.
28. Namias N., Samiian L., Nino D., et al. Incidence and susceptibility of pathogenic bacteria vary between intensive care units within a single hospital: implications for empiric antibiotic strategies. J Trauma 2000, 49:638-645.
29. Michel F., Franceschini B., Berger P., et al. Early antibiotic treatment for BAL-confirmed ventilator-associated pneumonia: a role for routine endotracheal aspirate cultures. Chest 2005, 127:589-597.
30. Nicasio A.M., Eagye K.J., Nicolau D.P., et al. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J Crit Care 2010, 25:69-77.
31. Souweine B., Veber B., Bedos J.P., et al. Diagnostic accuracy of protected specimen brush and bronchoalveolar lavage in nosocomial pneumonia: impact of previous antimicrobial treatments. Crit Care Med 1998, 26:236-244.
32. Micek S.T., Ward S., Fraser V.J., et al. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004, 125:1791-1799.
33. Singh N., Rogers P., Atwood C.W., et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit: a proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000, 162:505-511.
34. Luyt C.E., Guerin V., Combes A., et al. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med 2005, 171:48-53.
35. Povoa P., Coelho L., Almeida E., et al. C-reactive protein as a marker of ventilator-associated pneumonia resolution: a pilot study. Eur Respir J 2005, 25:804-812.
36. Hilf M., Yu V.L., Sharp J., et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989, 87:540-546.
37. Safdar N., Handelsman J., Maki D.G. Does combination antimicrobial therapy reduce mortality in gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2005, 4:519-527.
38. Heyland D.K., Dodek P., Muscedere J., et al. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 2008, 36:737-744.
39. Kumar A., Ellis P., Light B.R., et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 2010, 38:1773-1785.
40. Paul M., Benuri-Silbiger I., Soares-Weiser K., et al. Beta-lactam monotherapy versus beta-lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomizsed trials. BMJ 2004, 328:668.
41. Bliziotis I.A., Samonis G., Vardakas K.Z., et al. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 2005, 15(41):149-158.
42. Gruson D., Hilbert G., Vargas F., et al. Strategy of antibiotic rotation: long-term effect on incidence and susceptibilities of Gram-negative bacilli responsible for ventilator-associated pneumonia. Crit Care Med 2003, 31:1908-1914.
43. Fink M.P., Snydman D.R., Niederman M.S., et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother 1994, 38:547-557.
44. Sieger B., Berman S.J., Geckler R.W., et al. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group. Crit Care Med 1997, 25:1663-1670.
45. West M., Boulanger B.R., Fogarty C., et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther 2003, 25:485-506.
46. Joshi M., Bernstein J., Solomkin J., et al. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection. Piperacillin/tazobactam Nosocomial Pneumonia Study Group. J Antimicrob Chemother 1999, 43:389-397.
47. Chastre J., Wunderink R., Prokocimer P., et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008, 36:1089-1096.
48. ChastreJ W.M., Wolff M., Fagon J.Y., et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003, 290:2588-2598.
49. Michalopoulos A., Kasiakou S.K., Mastora Z., et al. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005, 9:R53-R59.
50. Baughman R.P., Kerr M.A. Ventilator-associated pneumonia patients who do not reduce bacterial from the lungs have a worse prognosis. J Intensive Care Med 2003, 18(5):269-274.